GlassScriptPhysician profile
Brian August Reichardt
NPI 1689802001
$891,827.62
in general payments reported to CMS, 2019-2025
29 companies · $285K in 2025
The $285K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $21K · 2021: $75K · 2022: $125K · 2023: $136K · 2024: $237K · 2025: $285K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $466K · Consulting Fee: $103K · Travel and Lodging: $64K · Food and Beverage: $21K · Education: $4,058 · Gift: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $465,525.75 |
| Consulting Fee | $102,812.00 |
| Travel and Lodging | $64,169.09 |
| Food and Beverage | $20,839.92 |
| Education | $4,057.61 |
| Gift | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $481,195.01 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Genzyme Corporation | $147,148.21 | 2022-2025 | |
| Glaxosmithkline, LLC. | $142,216.84 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $45,056.69 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39,582.98 | 2021-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $11,601.82 | 2019-2025 | Prolastin-C Liquid |
| Intuitive Surgical, INC. | $7,620.60 | 2024-2025 | |
| Genentech USA, INC. | $5,006.56 | 2019-2025 | |
| Amgen INC. | $4,949.68 | 2022-2025 | Tezspire |
| Regeneron Pharmaceuticals, INC. | $3,564.00 | 2025 | Dupixent |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Grifols Shared Services North America, INC. | $1,159.42 | 2023-2024 | Prolastin-C Liquid |
| Insmed, INC. | $192.09 | 2025 | Brinsupri, Arikayce |
| Philips North America LLC | $146.46 | 2019-2025 | Vest Therapy Und, Encore, (8874) Incourage |
| Takeda Pharmaceuticals U.S.A., INC. | $138.98 | 2020-2025 | Glassia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $105.35 | 2019 | |
| Sanofi-Aventis U.S. LLC | $86.22 | 2022 | |
| Ethicon INC. | $83.15 | 2021 | |
| Verona Pharma, INC. | $73.65 | 2025 | Ohtuvayre |
| Electromed, INC. | $49.39 | 2024 | Smartvest |
| Viatris Specialty LLC | $44.69 | 2025 | Yupelri |
| Medtronic, INC. | $42.25 | 2023 | Illumisite |
| Janssen Biotech, INC. | $41.16 | 2024 | Tremfya |
| Resmed Corp | $30.06 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.03 | 2019 | |
| Mylan Specialty L.P. | $22.78 | 2024 | Yupelri |
| Baxter Healthcare | $20.73 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Galvanize Therapeutics, INC | $14.10 | 2025 | Aliya System |
| Convatec INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Reichardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.